Happy New Year! This article summarizes the ten most popular life science news articles on the Momentum Technology website in the past year, and takes you back to review what happened in the subdivided fields such as pharmaceuticals, medical robots, and neural interventional implants.
TechNode’s top ten life science news in 2022 (ranked by reading volume, click on the title to jump to view):
1. Apple launches Apple Watch Series 8 and new Apple Watch SE: support wrist temperature sensing, car accident detection
Apple today launched the Apple Watch Series 8 and the new Apple Watch SE. Apple Watch Series 8 builds on Apple Watch design elements with a large, always-on Retina display, a tough, crack-resistant glass, up to 18 hours of battery life, and industry-leading health and safety features like an ECG app and fall detection On top of that, functions such as body temperature sensing, push back estimation of ovulation day, car accident detection and international roaming are added. The new Apple Watch SE offers the core Apple Watch experience, including activity tracking, high and low heart rate notifications, and SOS emergency contact, as well as new car accident detection features and a completely redesigned case back that perfectly fits three classic case looks. Both products are equipped with watchOS 9, introducing new and more customized dials such as the “Moon Phase” dial and the “Metropolis” dial, enhanced physical training apps, sleep stages, and a new medication app.
2. Zhongmei Ruikang, a small nucleic acid drug development company, completed nearly 200 million yuan in A+ round financing
Following the completion of the 120 million yuan A round of financing in February 2021, Ractigen Therapeutics, a global innovative small nucleic acid drug development company, today announced the completion of nearly 200 million yuan in the A+ round of financing. This round of financing was led by SDIC Venture Capital, Japan’s Eisai, Leading Venture Capital, Sino-Singapore Capital, Xianghe Chengdao, and the funds were mainly used to advance several preclinical projects to the clinical stage, expand nucleic acid production capacity, and Accelerate the process of internationalization.
3. Changjin Biotechnology, an edible microbial protein synthesis company, completed a Pre-A round of financing of 55 million yuan
Shanghai Changjin Biotechnology Co., Ltd., an edible microbial protein synthesis company, announced the completion of a Pre-A round of financing of 55 million yuan, led by Hillhouse Ventures, followed by Qingdao City Investment Financial Holdings and Shixin Capital.
4. The cell drug CDMO company Puxin Biotech completed nearly 100 million yuan Pre-A round of financing
Recently, Jiangsu Puxin Biomedicine Co., Ltd. (Puxin Bio) completed a Pre-A round of financing of nearly 100 million yuan. This round of financing was led by Puhua Capital, and the old shareholders Zhengxu Investment and Shengxingzhe Investment continued to increase their investment. The funds raised in this round will be used for the operation of the domestic R&D center and the establishment of the North Carolina R&D center in the United States, so as to better meet the growing demand for cell drug CDMO at home and abroad.
5. Hong Kong Asia Medical Group completes USD 400 million in Series D financing, led by Country Garden Ventures
Hong Kong Asia Medical Group (“Asia Medical”), an Asian cardiovascular medical brand, completed a US$400 million round of financing. This round of financing was led by Country Garden Ventures and Primavera Capital. Taikang Life Insurance, ICBC International, ABC International, Bank of Communications International, Hudson Bay, and Sherpa Investment followed the investment, and old shareholders Legend Capital and General Atlantic Investment continued to invest, and Haoyue Capital served as the financial advisor.
6. Jiayue Pharmaceutical completed nearly 200 million yuan in B+ round financing, led by Guanzi Venture Capital
On January 6, Jiayue Pharmaceutical announced the completion of nearly 200 million yuan in B+ round financing, led by Guanzi Venture Capital, and the old shareholders SDIC Venture Capital, Sequoia Capital China Fund and Linkage Venture Capital continued to follow. This is a new round of financing completed by Jiayue Medicine within half a year after completing the B round of financing in July 2021. This round of financing will be used to promote the mid-to-late stage clinical projects of the company’s multiple innovative drug pipelines.
7. Yousen Jianheng completed the A-round financing of 200 million yuan to develop innovative drugs for autoimmunity and tumors
Recently, Yousen Jianheng Bio-Pharmaceutical (Shanghai) Co., Ltd. announced the completion of the A-round financing of more than 200 million yuan. This round of financing was led by Shenzhen Sharing Investment, followed by Zhang Jiang Haoheng and Yingke Capital, and the original shareholders continued to participate in this round of investment. The funds raised will be used to carry out and accelerate the domestic and foreign clinical trials of UA007 and UA021, the development of small molecule drugs with multiple new targets, and the development of specific double antibody drugs.
8. Aibo Medical Robotics completed the Pre-A round of financing of 120 million yuan, accelerating the clinical registration of vascular interventional surgery robots
Recently, Shenzhen Aibo Medical Robot Co., Ltd. (hereinafter referred to as “Aibo Medical Robot”), which focuses on the research and development of vascular interventional surgery robots, has completed a Pre-A round of financing of 120 million yuan. This round of financing was jointly led by CDH VGC (Innovation and Growth Fund) and Yahui Investment, followed by Changan Private Capital, and Fang Changling Capital, the lead investor of the angel round, continued to invest in excess. The proceeds from the financing will be used to promote the clinical registration of the company’s vascular interventional surgery robot products, strengthen team building, and accelerate product development.
9. Focusing on the research and development of neural interventional implant medical device products, Likai Technology has completed a B+ round of financing of over 200 million yuan
In March 2022, Shanghai Likai Technology Co., Ltd. (referred to as “Likai Technology”) completed the B+ round of financing exceeding 200 million yuan. This round of financing was jointly led by Shenzhen Venture Capital and Lingang Science and Technology Venture Capital. , Shanghai Science and Technology Innovation Fund, and Betta Fund followed suit, and the old shareholder Hengxu Capital made additional investment. WinX Capital continues to act as exclusive financial advisor. Prior to this, Likai Technology has received investment from Hillhouse Ventures, Hengxu Capital, Yangyun Capital, Taifu Capital and Taiyu Investment under Tigermed.
10. Jingyu Medical completed the D+ round financing of 300 million yuan, deeply cultivating the field of deep brain stimulation therapy
On February 16, SceneRay announced the completion of a D+ round of financing of RMB 300 million, jointly led by Sequoia China and Hillhouse Ventures. This financing is another successful financing for Jingyu Medical after the completion of the D round of financing of more than 100 million yuan led by Yanchuang Capital in April 2020. Huaxing Capital acted as the exclusive financial advisor.
recommend:
Top 10 Most Popular News in 2022｜MotionPoint Technology Year-End Review
Top 10 Most Popular Original Articles in 2022｜MotionPoint Technology Year-End Review
Top 10 Consumer Technology News in 2022｜MotionPoint Technology Year-End Review
Top 10 Sustainability News in 2022｜Motionpoint Technology Year-End Review
